Ingredion Incorporated Reports Second Quarter 2026 Results
Ingredion (NYSE: INGR) reported Q2 2026 EPS of $1.78 (reported) and $2.82 (adjusted), versus $2.99 and $2.87 in Q2 2025. Reported and adjusted operating income fell 31% and 5% year over year. Full-year guidance was reaffirmed: reported EPS $9.15-$9.75, adjusted $10.30-$10.90, reflecting sale of a majority Pakistan stake. Shareholders accepted Ingredion’s 595 pence all-cash offer for Tate & Lyle.
How this was made
The 30-second read
Why it matters
The key tradable elements are (1) quarterly EPS and operating income declines versus 2Q25, (2) reaffirmed full-year reported EPS $9.15 to $9.75 and adjusted EPS $10.30 to $10.90, and (3) transaction momentum from Pakistan stake sale completion and Tate & Lyle shareholder approval (July 28).
Market read
This is a combined earnings and M&A progress update with explicit EPS guidance ranges and deal-approval milestones, likely driving near-term positioning around margin durability and integration risk.
What to watch
Non-GAAP adjustments and one-time items (impairment, Cabo closure costs, Argo thermal event) may mask trend deterioration; traders should separate adjusted EPS from reported EPS and track FX sensitivity and production-rate normalization.
Background
Ingredion reported 2Q26 results, reaffirmed amended full-year guidance, completed the sale of a majority stake in its Pakistan business, and noted shareholder approval for its all-cash offer to acquire Tate & Lyle.
Ticker impact
Ingredion reported 2Q26 EPS of $1.78 (reported) and $2.82 (adjusted) and reaffirmed full-year EPS guidance ranges.
Shares may face two-sided reaction: downside risk from weaker reported/adjusted operating income, offset by deal completion momentum and guidance held.
The article provides hard quarterly results and explicit full-year EPS ranges, while also stating shareholder approval for the Tate & Lyle acquisition and completion of the Pakistan majority-stake sale, both of which can move risk perception.
Market effects
Ingredient suppliers tied to food and beverage manufacturing may see read-across on demand durability (Texture & Healthful Solutions growth) versus margin pressure (FX, tapioca costs, restructuring/impairments).
LATAM segment commentary highlights FX and demand headwinds, while U.S./CAN notes operational normalization at Argo plant.
The Tate & Lyle acquisition integration planning and Pakistan stake sale can shift competitive positioning and capital allocation expectations across global ingredients.
Counterpoint
Despite reaffirmed EPS ranges, the reported and adjusted operating income declines suggest underlying margin and volume pressures may be larger than the guidance implies, making the deal-driven optimism potentially fragile.
Key entities
- public_companyIngredion Incorporated
Reported 2Q26 results and reaffirmed full-year EPS guidance; progressing Tate & Lyle acquisition and completed Pakistan majority-stake sale.
- public_companyTate & Lyle
Shareholders approved Ingredion’s recommended 595 pence all-cash offer on July 28, advancing the acquisition process.
